Titre : Épilepsies myocloniques progressives

Épilepsies myocloniques progressives : Questions médicales fréquentes

Termes MeSH sélectionnés :

Case-Control Studies
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Épilepsies myocloniques progressives : Questions médicales les plus fréquentes", "headline": "Épilepsies myocloniques progressives : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Épilepsies myocloniques progressives : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-06", "dateModified": "2025-03-03", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Épilepsies myocloniques progressives" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Épilepsies myocloniques", "url": "https://questionsmedicales.fr/mesh/D004831", "about": { "@type": "MedicalCondition", "name": "Épilepsies myocloniques", "code": { "@type": "MedicalCode", "code": "D004831", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C10.228.140.490.493.063" } } }, "about": { "@type": "MedicalCondition", "name": "Épilepsies myocloniques progressives", "alternateName": "Myoclonic Epilepsies, Progressive", "code": { "@type": "MedicalCode", "code": "D020191", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Pasquale Striano", "url": "https://questionsmedicales.fr/author/Pasquale%20Striano", "affiliation": { "@type": "Organization", "name": "IRCCS Istituto \"Giannina Gaslini\", Genova, Italy; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genova, Italy." } }, { "@type": "Person", "name": "Marte Syvertsen", "url": "https://questionsmedicales.fr/author/Marte%20Syvertsen", "affiliation": { "@type": "Organization", "name": "Department of Neurology, Drammen Hospital, Vestre Viken Health Trust, Oslo, Norway." } }, { "@type": "Person", "name": "Deb K Pal", "url": "https://questionsmedicales.fr/author/Deb%20K%20Pal", "affiliation": { "@type": "Organization", "name": "Department of Basic & Clinical Neurosciences, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK." } }, { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Jeanette Koht", "url": "https://questionsmedicales.fr/author/Jeanette%20Koht", "affiliation": { "@type": "Organization", "name": "Department of Neurology, Drammen Hospital, Vestre Viken Health Trust, Oslo, Norway." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "A case-control study on immunologic markers of patients with vitiligo.", "datePublished": "2022-10-14", "url": "https://questionsmedicales.fr/article/36244264", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.biopha.2022.113785" } }, { "@type": "ScholarlyArticle", "name": "Case-Control Study of Long COVID, Sapporo, Japan.", "datePublished": "2023-04-12", "url": "https://questionsmedicales.fr/article/37044126", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3201/eid2905.221349" } }, { "@type": "ScholarlyArticle", "name": "Endothelium-biomarkers for postthrombotic syndrome: a case-control study.", "datePublished": "2023-03-29", "url": "https://questionsmedicales.fr/article/37016998", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/MBC.0000000000001192" } }, { "@type": "ScholarlyArticle", "name": "Risk Factors for Postoperative Pneumonia: A Case-Control Study.", "datePublished": "2022-07-08", "url": "https://questionsmedicales.fr/article/35875004", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fpubh.2022.913897" } }, { "@type": "ScholarlyArticle", "name": "Significance of temperature in antimuscarinic toxicity: a case-control study.", "datePublished": "2022-06-23", "url": "https://questionsmedicales.fr/article/35735006", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/15563650.2022.2088378" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies du système nerveux", "item": "https://questionsmedicales.fr/mesh/D009422" }, { "@type": "ListItem", "position": 3, "name": "Maladies du système nerveux central", "item": "https://questionsmedicales.fr/mesh/D002493" }, { "@type": "ListItem", "position": 4, "name": "Encéphalopathies", "item": "https://questionsmedicales.fr/mesh/D001927" }, { "@type": "ListItem", "position": 5, "name": "Épilepsie", "item": "https://questionsmedicales.fr/mesh/D004827" }, { "@type": "ListItem", "position": 6, "name": "Syndromes épileptiques", "item": "https://questionsmedicales.fr/mesh/D000073376" }, { "@type": "ListItem", "position": 7, "name": "Épilepsies myocloniques", "item": "https://questionsmedicales.fr/mesh/D004831" }, { "@type": "ListItem", "position": 8, "name": "Épilepsies myocloniques progressives", "item": "https://questionsmedicales.fr/mesh/D020191" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Épilepsies myocloniques progressives - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Épilepsies myocloniques progressives", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-06", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Épilepsies myocloniques progressives", "description": "Comment diagnostiquer une épilepsie myoclonique progressive ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels signes cliniques indiquent une épilepsie myoclonique ?\nL'EEG est-il essentiel pour le diagnostic ?\nPeut-on diagnostiquer cette épilepsie à tout âge ?", "url": "https://questionsmedicales.fr/mesh/D020191?mesh_terms=Case-Control+Studies&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Épilepsies myocloniques progressives", "description": "Quels sont les principaux symptômes des épilepsies myocloniques progressives ?\nLes myoclonies sont-elles toujours présentes ?\nY a-t-il des troubles cognitifs associés ?\nLes crises peuvent-elles varier en intensité ?\nLes symptômes peuvent-ils s'aggraver avec le temps ?", "url": "https://questionsmedicales.fr/mesh/D020191?mesh_terms=Case-Control+Studies&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Épilepsies myocloniques progressives", "description": "Peut-on prévenir les épilepsies myocloniques progressives ?\nLes facteurs génétiques jouent-ils un rôle ?\nLes traumatismes crâniens peuvent-ils déclencher des crises ?\nLe stress peut-il aggraver les symptômes ?\nY a-t-il des recommandations pour les patients ?", "url": "https://questionsmedicales.fr/mesh/D020191?mesh_terms=Case-Control+Studies&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Épilepsies myocloniques progressives", "description": "Quels traitements sont disponibles pour cette épilepsie ?\nLes médicaments sont-ils toujours efficaces ?\nY a-t-il des options chirurgicales ?\nLes thérapies complémentaires sont-elles utiles ?\nComment évaluer l'efficacité du traitement ?", "url": "https://questionsmedicales.fr/mesh/D020191?mesh_terms=Case-Control+Studies&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Épilepsies myocloniques progressives", "description": "Quelles complications peuvent survenir ?\nLes patients sont-ils à risque de dépression ?\nLes crises peuvent-elles entraîner des accidents ?\nY a-t-il un risque accru de mortalité ?\nLes troubles du sommeil sont-ils fréquents ?", "url": "https://questionsmedicales.fr/mesh/D020191?mesh_terms=Case-Control+Studies&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Épilepsies myocloniques progressives", "description": "Quels sont les facteurs de risque connus ?\nL'âge influence-t-il le risque d'épilepsie ?\nLes infections cérébrales sont-elles un facteur de risque ?\nLes troubles métaboliques peuvent-ils jouer un rôle ?\nLe sexe influence-t-il le risque d'épilepsie ?", "url": "https://questionsmedicales.fr/mesh/D020191?mesh_terms=Case-Control+Studies&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une épilepsie myoclonique progressive ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'examen clinique, l'EEG et l'imagerie cérébrale." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques, un EEG et des examens d'imagerie sont souvent nécessaires." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent une épilepsie myoclonique ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des secousses musculaires involontaires et des troubles cognitifs peuvent indiquer cette épilepsie." } }, { "@type": "Question", "name": "L'EEG est-il essentiel pour le diagnostic ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'EEG montre des anomalies typiques des crises myocloniques." } }, { "@type": "Question", "name": "Peut-on diagnostiquer cette épilepsie à tout âge ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, bien que les symptômes apparaissent souvent à l'adolescence ou au début de l'âge adulte." } }, { "@type": "Question", "name": "Quels sont les principaux symptômes des épilepsies myocloniques progressives ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des myoclonies, des crises tonico-cloniques et une détérioration cognitive." } }, { "@type": "Question", "name": "Les myoclonies sont-elles toujours présentes ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les myoclonies sont un symptôme caractéristique de cette condition." } }, { "@type": "Question", "name": "Y a-t-il des troubles cognitifs associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une détérioration cognitive progressive est souvent observée." } }, { "@type": "Question", "name": "Les crises peuvent-elles varier en intensité ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'intensité et la fréquence des crises peuvent varier d'un patient à l'autre." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils s'aggraver avec le temps ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la progression des symptômes est typique des épilepsies myocloniques progressives." } }, { "@type": "Question", "name": "Peut-on prévenir les épilepsies myocloniques progressives ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de méthode de prévention, mais un diagnostic précoce peut aider." } }, { "@type": "Question", "name": "Les facteurs génétiques jouent-ils un rôle ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines formes d'épilepsies myocloniques progressives ont une composante génétique." } }, { "@type": "Question", "name": "Les traumatismes crâniens peuvent-ils déclencher des crises ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traumatismes crâniens peuvent augmenter le risque de crises chez les individus prédisposés." } }, { "@type": "Question", "name": "Le stress peut-il aggraver les symptômes ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut exacerber les crises et les symptômes associés." } }, { "@type": "Question", "name": "Y a-t-il des recommandations pour les patients ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Les patients sont conseillés d'éviter les déclencheurs connus et de suivre leur traitement." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour cette épilepsie ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des médicaments antiépileptiques et parfois des thérapies complémentaires." } }, { "@type": "Question", "name": "Les médicaments sont-ils toujours efficaces ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les médicaments peuvent réduire les crises, mais leur efficacité varie selon les patients." } }, { "@type": "Question", "name": "Y a-t-il des options chirurgicales ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La chirurgie est rare mais peut être envisagée dans certains cas résistants au traitement." } }, { "@type": "Question", "name": "Les thérapies complémentaires sont-elles utiles ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Certaines thérapies comme la thérapie comportementale peuvent aider à gérer les symptômes." } }, { "@type": "Question", "name": "Comment évaluer l'efficacité du traitement ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité est évaluée par la réduction de la fréquence et de l'intensité des crises." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des blessures dues aux crises et des troubles cognitifs sévères." } }, { "@type": "Question", "name": "Les patients sont-ils à risque de dépression ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients peuvent développer une dépression en raison de la maladie et de ses effets." } }, { "@type": "Question", "name": "Les crises peuvent-elles entraîner des accidents ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les crises peuvent provoquer des accidents, notamment lors de la conduite." } }, { "@type": "Question", "name": "Y a-t-il un risque accru de mortalité ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque de mortalité peut être plus élevé en raison de complications liées aux crises." } }, { "@type": "Question", "name": "Les troubles du sommeil sont-ils fréquents ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les troubles du sommeil sont courants chez les patients atteints d'épilepsies myocloniques." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque connus ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux d'épilepsie et certains troubles neurologiques augmentent le risque." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque d'épilepsie ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'âge d'apparition est souvent entre 10 et 30 ans pour ces épilepsies." } }, { "@type": "Question", "name": "Les infections cérébrales sont-elles un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines infections peuvent augmenter le risque de développer des épilepsies." } }, { "@type": "Question", "name": "Les troubles métaboliques peuvent-ils jouer un rôle ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains troubles métaboliques sont associés à un risque accru d'épilepsie." } }, { "@type": "Question", "name": "Le sexe influence-t-il le risque d'épilepsie ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines études montrent que le sexe peut influencer la prévalence des épilepsies." } } ] } ] }

Sources (10000 au total)

Endothelium-biomarkers for postthrombotic syndrome: a case-control study.

The postthrombotic syndrome (PTS) is a long-term complication of deep venous thrombosis (DVT). Increase knowledge on the PTS pathophysiology and novel biomarkers are needed in order to predict PTS dev... A case-control study was conducted. Inclusion criteria were symptomatic and confirmed DVT patients treated with anticoagulants for at least 3 months. Villalta score was performed at the time of inclus... Thirty two patients and 61 controls were included. PTS patients showed higher levels of CEC (0.56/μl (0.34-1.5) vs. 0.20/μl (0.11-0.77); P = 0.04) and EPC (0.75/μl (0.38-1.52) vs. 0.09/μl (0.05-0.82);... The formation and early resolution of DVT are characterized by inflammation and endothelial/platelet activation. We have identified possible novel biomarkers such as CEC, EPC and fractalkine for the d...

Risk Factors for Postoperative Pneumonia: A Case-Control Study.

Postoperative pneumonia is a preventable complication associated with adverse outcomes, that greatly aggravates the medical expenses of patients. The goal of our study is to identify risk factors and ... A matched 1:1 case-control study, including adult patients who underwent surgery between January 2020 and June 2020, was conducted in the Second Affiliated Hospital of Kunming Medical University in Ch... Out of 17,190 surgical patients, 264 (1.54%) experienced postoperative pneumonia. Increased age, chronic obstructive pulmonary disease, emergency surgery, postoperative reduced albumin, prolonged vent... Postoperative pneumonia is associated with severe clinical outcomes. We identified six independent risk factors that can aid in risk stratification and management of patients at risk of postoperative ... www.chictr.org.cn, identifier: chiCTR2100045986....

Significance of temperature in antimuscarinic toxicity: a case-control study.

Antimuscarinic toxicity can result in temperature dysregulation, but the clinical significance of this is unclear. The objective of this study was to compare peak temperatures between antimuscarinic p... This was a case-control analysis at two large, urban, academic medical centers from January 1, 2016, through December 31, 2021. We compared peak temperature (... Fifty-six patients met inclusion criteria of which 23 developed severe outcomes: 16 seizures, 9 cases with hypotension, 5 intubations, and 2 ventricular dysrhythmias. Tmax amongst all patients ranged ... Maximum temperatures did not differ between patients with and without severe outcomes in the setting of antimuscarinic toxicity, and temperature was poorly predictive of outcomes. Our findings suggest...

A postmortem case control study of asbestos burden in lungs of malignant mesothelioma cases.

Asbestos lung content is regarded as the most reliable tool for causal attribution of malignant mesothelioma (MM) to previous asbestos exposures. However, there is a lack of studies on asbestos burden... Asbestos lung content has been assessed on formalin-fixed lung fragments using scanning electron microscopy coupled with energy dispersion spectroscopy (SEM-EDS) on individuals deceased from MM (cases... Asbestos and asbestos bodies (ABs) were found, respectively, in 73.7% and 43.2% of cases and in 28 and 22% of controls; in MM cases the most represented asbestos types were crocidolite and amosite, wh... The results suggest a correlation between asbestos burden in lungs and MM risk. The different concentration of chrysotile, as well as the different width of asbestos fibers in MM males and females mig...

Anemia and Idiopathic Intracranial Hypertension: A Case-Control Study.

Idiopathic intracranial hypertension (IIH) is a condition that mostly affects obese women of childbearing age but has been reported to be temporally related to new diagnoses of anemia. Despite these r... Consecutive IIH patients were recruited from neuro-ophthalmology clinics and matched by age and sex to consecutive patients attending neuro-ophthalmology clinics with diagnoses other than IIH. Complet... One hundred twenty-three IIH patients and 113 controls were included in the study. More IIH patients than controls had anemia (22.8%, 28/123 vs 10.6%, 12/113, P = 0.01) with an odds ratio of 2.48 (95%... Idiopathic intracranial hypertension patients have a higher prevalence of anemia compared with non-IIH neuro-ophthalmology patients. The anemia was mostly mild and may be explained by other factors re...

Study on the association between adverse drug reactions to opioids and gene polymorphisms: a case-case-control study.

Adverse drug reactions (ADRs) caused by opioid drugs show individual differences. Our objective was to explore the association between gene polymorphism and ADRs induced by opioid drugs.... Evidence-based medical data analysis was conducted for genes related to ADRs induced by opioid drugs to select target genes. Sixty patients with cancer pain who had ADRs after taking opioid drugs (mor... Based on a database search and evidence-based medical data, we identified CYP2D6*10, CYP3A5*3, ABCB1, and OPRM1 as target genes for detection. The results of statistical analysis showed no significant... Polymorphism of ABCB1 (062rs1045642) is related to ADRs caused by oxycodone, and the incidence of ADRs is higher with the allele T. Polymorphism of ABCB1 is expected to become a clinical predictor of ...

Systemic hormone therapy and dementia: A nested case-control and co-twin control study.

The effect of systemic hormone therapy (HT) on dementia risk is unclear. Our aim was to investigate the association between HT and dementia.... This register-based study consists of a nested case-control study and a co-twin control design, which controls for familial confounding, including shared genetics.... Through Danish national registries from 1995 to 2011, we identified: a) 2700 female singletons with incident dementia and 13,492 matched controls; b) 288 female twins with incident dementia and co-twi... The odds ratio (OR) for the association between systemic HT and dementia was 1.05, 95% CI = [0.93-1.19] in singletons and 2.10, 95% CI = [0.99-4.46] in twins. A statistically significant association w... Using Danish nationwide registries and controlling for education and for familial factors in a subsample, systemic HT was found to be associated with increased dementia risk if used before 2003, when ...